[Trials with gabapentin monotherapy in patients with complex partial or secondary generalized seizures].
Neurontin (Gabapentin) is indicated as an add-on treatment of partial epileptic seizures. Clinical studies demonstrating the efficacy of Neurontin as monotherapy are currently on going. This article describes the design of 2 clinical trials of Gabapentin as monotherapy for epileptic seizures.
Pierce
M W
MW
Parke-Davis, Abteilung für Pharmazeutische Forschung, Warner-Lambert, Ann Arbor, Michigan, USA.
Shokry
A
A
D000085:Acetates / Q000009:adverse effects / Q000627:therapeutic use*; D000588:Amines; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use*; D003509:Cyclohexanecarboxylic Acids; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004569:Electroencephalography / Q000187:drug effects; D004828:Epilepsies, Partial / Q000188:drug therapy*; D017029:Epilepsy, Complex Partial / Q000188:drug therapy*; D000077206:Gabapentin; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D016896:Treatment Outcome; D005680:gamma-Aminobutyric Acid
D000085:Acetates; D000588:Amines; D000927:Anticonvulsants; D003509:Cyclohexanecarboxylic Acids; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin